Xie, W., Ravi, P., Buyse, M. E., Halabi, S., Kantoff, P. W., Sartor, O., … Sweeney, C. (2023). 1773P ICECaP-2: Validation of metastasis-free survival (MFS) as a surrogate for overall survival (OS) in localized prostate cancer (LPC) in a more contemporary era. In Annals of Oncology (Vol. 34, pp. S958–S959). Elsevier BV. https://doi.org/10.1016/j.annonc.2023.09.2723

Xie, W., P. Ravi, M. E. Buyse, S. Halabi, P. W. Kantoff, O. Sartor, H. R. Soule, et al. “1773P ICECaP-2: Validation of metastasis-free survival (MFS) as a surrogate for overall survival (OS) in localized prostate cancer (LPC) in a more contemporary era.” In Annals of Oncology, 34:S958–59. Elsevier BV, 2023. https://doi.org/10.1016/j.annonc.2023.09.2723.

Xie W, Ravi P, Buyse ME, Halabi S, Kantoff PW, Sartor O, et al. 1773P ICECaP-2: Validation of metastasis-free survival (MFS) as a surrogate for overall survival (OS) in localized prostate cancer (LPC) in a more contemporary era. In: Annals of Oncology. Elsevier BV; 2023. p. S958–9.

Xie, W., et al. “1773P ICECaP-2: Validation of metastasis-free survival (MFS) as a surrogate for overall survival (OS) in localized prostate cancer (LPC) in a more contemporary era.” Annals of Oncology, vol. 34, Elsevier BV, 2023, pp. S958–59. Crossref, doi:10.1016/j.annonc.2023.09.2723.

Xie W, Ravi P, Buyse ME, Halabi S, Kantoff PW, Sartor O, Soule HR, Clarke N, Collette L, Dignam J, James ND, Fizazi K, Gillessen S, Mottet N, Murphy LR, Parulekar WR, Sandler H, Tombal B, Williams S, Sweeney C. 1773P ICECaP-2: Validation of metastasis-free survival (MFS) as a surrogate for overall survival (OS) in localized prostate cancer (LPC) in a more contemporary era. Annals of Oncology. Elsevier BV; 2023. p. S958–S959.